Discover AMVUTTRA® (vutrisiran) (No CEUs)


Join our distinguished faculty as they discuss recognizing, diagnosing, and managing polyneuropathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis.  They will provide an overview of hATTR amyloidosis and review the clinical profile of AMVUTTRA® (vutrisiran) a treatment for the polyneuropathy of hATTR amyloidosis in adults.  AMVUTTRA has warnings and precautions for reduced serum vitamin A levels and recommended supplementation.  The most common adverse reactions are arthralgia, dyspnea, and vitamin A decreased.  For additional information about AMVUTTRA, please see the Important Safety Information and full Prescribing information at




The content in this Industry Expert Theater  was created independently by the sponsor.  The views and/or opinions do not necessarily reflect the views of HFSA or its members.  The activity "Discover AMVUTTRA® (vutrisiran) (no CEUs)" is not sponsored or endorsed by the HFSA.  The Industry Expert Theater is not offered in the HFSA-accredited continuing education catalog; therefore, it is ineligible for continuing education units.  No committee members or representatives of the HFSA has been involved in the planning of this activity.

Learning Objectives: 


  • Provide a disease overview of hATTR amyloidosis 
  • Discuss a hypothetical patient case, including symptom presentation and management goals 
  • Review the clinical efficacy and safety of AMVUTTRA® (vutrisiran) as a treatment option for the polyneuropathy of hATTR amyloidosis in adults 
  • Provide an overview of Alnylam AssistTM, a patient support program for adults who have been prescribed AMVUTTRA for the polyneuropathy of hATTR amyloidosis



  • Amanda Peltier, MD, MS, Vanderbilt University Medical Center
  • Brett Sperry, MD, Saint Luke's Mid America Heart Institute 


AMVUTTRA and its associated logo are trademarks of Alnylam Pharmaceuticals, Inc.

© 2023 Alnylam Pharmaceuticals, Inc.  All rights reserved.  AMV-USA-00533





Powered by Oasis.